Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Overview of Dr. Sweet
Dr. Kendra Sweet is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. She received her medical degree from Virginia Commonwealth University School of Medicine and has been in practice 19 years. Dr. Sweet accepts several types of health insurance, listed below. She is one of 200 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 48 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2007 - 2010
Virginia Commonwealth University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2010 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2014, 2016-2017
Clinical Trials
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
- Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Aug 29
- Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Publications & Presentations
PubMed
- Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Dimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, David A Sallman, Qianxing Mo
Blood Cancer Discovery. 2026-02-11 - Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.Luis E Aguirre, Haesook T Kim, Hany Elmariah, Stacey M Frumm, Amar H Kelkar
Blood Advances. 2026-01-26 - First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level.Naveen Pemmaraju, Marco Herling, Kendra L Sweet, Anthony S Stein, Sumithira Vasu
Haematologica. 2026-01-15
Journal Articles
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseKendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseKendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
Abstracts/Posters
- SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic SyndromeKendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and VenetoclaxKendra L. Sweet, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
- Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) PatientsKendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseOctober 2018
- State of the Art Update and Next Questions: Acute Myeloid LeukemiaOctober 2017
Press Mentions
Adding Ruxolitinib to TKI Treatments Enhances Molecular Response in Chronic Myeloid LeukemiaSeptember 24th, 2024- S1712 Supports Adding Ruxolitinib to TKIs for CMLSeptember 20th, 2024
- Leukemia Patients Consider Stopping Drug to See if They’re CuredDecember 12th, 2019
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOCoventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
